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Two different forms of rubella virus E2 glycoproteins were expressed in insect cells: intact wild-type E2 and a soluble 
form of E2 (E2~Tm) glycoprotein, in which the C-terminal membrane-anchor domain was deleted. E2ATm behaved as a 
secretory protein and was secreted abundantly (5 mg/liter) from insect cells. In contrast to wild-type E2 (36 kDa), E2ATm 
was secreted into the media and was detected as two species (33 and 30 kDa). Lectin binding assays in conjunction with 
glycoeidase analyses revealed that both intracellular wild-type E2 and E2ATm contained only N-linked glycans, while the 
two secreted forms of E2ATm were found to differ in their glycosylation, with the 30-kDa form having only N-linked glycans 
while the 33-kDa species had both N-linked and O4inked glycans. The secreted E2ATm species were purified by precipitation 
between 20 and 40% saturation with (NH4)2SO4 and retained full antigenicity. The levels of antibodies elicited in mice 
immunized with purified E2ATm showed that the immunogenicity ofsecreted E2LkT m compared favorably to that of natural 
virion E2. © 1995 Academic Press, Inc. 
Rubella virus (RV), the causative agent of German mea- 
sles, is a small enveloped positive-stranded RNA virus 
belonging to the Togaviridae family (1). infection during 
early pregnancy results in various birth defects, collec- 
tively known as congenital rubella syndrome (CRS) (1). 
The RV virion contains three structural proteins, E1 (58 
kDa), E2 (42 to 47 kDa), and C (33 kDa) (2). E1 and E2 
are membrane glycoproteins that exist as a heterodimer 
and form the viral spike complexes on the surface of the 
virion (3). The capsid (C) protein is associated with the 
genomic RNA forming the nucleocapsid (2). The biologi- 
cal role of E2 is not well defined, but strain-specific epi- 
topes (4) and at least one neutralizing domain have been 
reported (5). Antibodies to E1 are predominant following 
most RV infections, but antibodies to E2 are more abun- 
dant in ORS than in other forms of RV infection (6). Very 
few E2-specific monoclonal antibodies are isolated com- 
pared to the large number directed against E1 when mice 
are immunized with whole RV (5, 7), presumably due to 
poor immunogenicity of E2 in native virions. This may be 
due to the fact that E2 epitopes are buried under E1 in 
the heterodimeric spike complexes on the virion surface 
(8). E2 from the RV strain M33 contains three large, com- 
plex-type N-linked (9, 10) and several smaller O-linked 
carbohydrates (10). 
Due to the nature of E2 and E1 glycoproteins that exist 
as a heterodimer and form the viral spike complexes on 
the surface of the virion, no preparations of E2 proteins 
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from the virion or recombinant sources have been satis- 
factory in terms of ease of large scale preparations or 
good retention of antigenicity (11- 15). The production of 
an antigenic, secreted form of E2 protein from insect cells 
will provide large quantities of material for biological and 
immunological studies. In order to express E2 protein 
abundantly in a form that can be simply purified from 
cell culture, we have converted the membrane-bound E2 
protein into a secretory protein and expressed it using 
the baculovirus-insect cell system (16). 
It has been shown that viral transmembrane glycopro- 
teins are secreted from cells if the transmembrane an- 
chor sequences are deleted (17, 18). This strategy was 
used to produce a soluble form of E2 protein by trunca- 
tion of the C-terminus of E2 before the anchor region 
(12). To create the soluble form of E2 protein (E2~Tm), 
the plasmid pE2 containing the RV E2 cDNA (12) was 
digested to completion with Xbal, followed by partial di- 
gestion with Ncol to release the DNA fragment encoding 
60 C-terminal amino acids of E2 protein (19). The Xbal 
and Ncol termini of the truncated plasmid were made 
blunt with T4 DNA polymerase and recircularized using 
T4 DNA ligase. The ends of the EcoRI-Hindl l l  fragment 
containing E2ATm cDNA were made blunt and inserted 
into the unique Nhel site (made blunt) of the transfer 
vector pBlueBac (/gLI) (from Invitrcgen) to form pAc- 
BlueBac-E2ATm (Fig. 1). The constructed recombinant 
plasmid was confirmed by restriction analysis. The cDNA 
construct contains the capsid (C) protein translation start 
site as well as nucleotides specifying the first eight 
amino acids and 55 carboxyl-terminal residues of the C 
protein, including the putative E2 signal sequence (19) 
(Fig. 1). Cotransfection of Sf9 insect cells with this recom- 
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FiG. 1. Schematic diagram of RV E2 and E2ATm cDNA. The three 
RV structural proteins are encoded by a 24S subgenomic mRNA and 
the order of translation is NH2-C-E2-E1 -COOH. Respective portions 
of RV capsid (C), E2, and E1 genes are indicated on the cDNA fragments 
24S, F2, and E2ATm. Intergene borders are marked by vertical lines, 
signal peptides are indicated by open boxes, and transmembrane re- 
gions by solid boxes. The E2 gene was isolated from the 24S cDNA 
with a portion of the capsid gene and inserted into the unique BamHI 
cloning site in the transfer vector pAcYMI. The removal of the putative 
tramsmembrane domain from E2 results in the cDNA E2ATm, which 
was inserted into the unique Nhel cloning site of the baculovirus trans- 
fer vector pBlueBac (fiLl). The initiation codon of capsid protein was 
utilized for the expression of both E2 proteins. The RV E2 and E2z&Tm 
cDNA were expressed under the control of the polyhedrin promoter. 
The bar represents approximately 500 nucleotides; N-linked glycosyla- 
tion sites are indicated (Y). E and H denote the EeoRI and Hindlll 
restriction sites flanking the 5'- and 3'-ends of the constructs, respec- 
tively. The blunt-ended Pstl site, where the deoxyoligonucleotide was 
inserted, is marked with arrowhead. 
binant plasmid and wild-type baculovirus, Autographica 
califomica polyhedrosis virus (AcNPV), DNA resulted in 
homologous recombination in vivo and replacement of 
the polyhedrin coding region with that of E2Z~Tm cDNA. 
AcNPV sequences present in the transfer vector and viral 
DNA give rise to recombinant baculoviruses that were 
identified by the formation of blue plaques, which were 
also viral occlusion negative (20). Clonal recombinant 
baculoviruses expressing intracellular and secreted BV 
E2 proteins were identified by immunoblot analysis (21) 
of infected cell extracts and culture supernatants. The 
recombinant baculovirus (Ac-E2Z&Tm) was purified and 
used for the production of E2z&Tm protein. 
Pulse-chase analysis was used to evaluate the ex- 
pression and secretion of E2z&Tm protein. Sf9 cells in- 
fected with Ac-E2ATm were pulse-labeled with [35S]- 
methionine for 15 min and chased with 1 mM unlabeled 
methionine for 24 hr (22). RV proteins were immunopre- 
cipitated with human anti-RV sera and analyzed by SDS- 
PAGE as described previously (23). The amount of 
expressed intracellular E2zSTm protein (designated 
iE2z&Tm) (32 kDa) increased from 0 to 24 hr of chase 
(Fig. 2A, cells), and two secreted E2Z~Tm (designated 
sE2/kTm) species (33 and 30 kDa) were detected in the 
culture medium only after 24 hr of chase (Fig. 2A, media). 
To determine the processing of N-linked glycosylation in 
expressed E2 proteins, the immunoprecipitated E2 pro- 
teins were digested with endoglycosidase H (endo Hi, 
an enzyme which selectively cleaves immature high man- 
nose N-linked oligosaccharides within the compartments 
of the endoplasmic reticulum (ER) and the mediaI-Golgi 
apparatus (24). Digestion of iE2z&Tm with endo H de- 
creased its molecular weight from approximately 32 to 
25 kDa (Fig. 2A, cells, 0-hr chase). Two iE2Z~Tm species 
(29 and 27 kDa) were partially resistant to endo H diges- 
tion (Fig. 2A, cells, 2-hr chase). In contrast, the electro- 
phoretic mobil/ties of both sE2ATm species were not 
affected by digestion with endo H (Fig. 2A, media). Insect 
cells have the capability to convert high mannose N- 
linked glycans to endo H-resistant forms (25-27). The 
endo H-resistant oligosaccharides consist of the Man3GI- 
cNA% core of N-glycans that may also have a fucose 
attached (28). 
In COS cells transfected with RV E2 cDNA, a small 
amount of E2 was found in the medium (unpublished 
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FIG, 2. Pulse-chase analysis of RV E2 and RV E2z~Tm expression. 
Sf9 cells infected with Ac-E22~Tm(A) or Ac-E2(B) were pulse-labeled 
with [36S]methionine and chased with 1 mM unlabeled methionine as 
described (30). RV proteins were immunoprecipitated with human anti- 
RV sera from culture media and cellular lysates of infected cells. Sam- 
ples were taken after the chase periods shown above each lane. Sam- 
ples were treated with buffer only ( - )  or endo H (+). Two E2ATm 
species were secreted into the culture media and not altered by endo 
H digestion (single and double arrowheads). Intracellular E2 used for 
endo H digestion (Hi was from immunoprecipitates after a 24-hr chase 
period. Positions of molecular weight markers are shown on the left 
(kDa). 
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data). It is unclear whether proteolytic leavage occurred 
to release E2 into the medium. To address the question 
as to whether sF2z~Tm protein present in the culture 
medium of Sf9 cells was due to secretion and not to 
proteolysis, we have isolated recombinant baculovirus 
(Ac-E2) expressing membrane-bound E2 protein. The 
plasmid pE2 containing the RV E2 cDNA (12) was di- 
gested with Pstl, the protruding 5'-ends were removed 
by treatment with T4 DNA polymerase and the plasmid 
was recircularized in the presence of .a deoxyoligo- 
nucleotide (CTAGTCTAGACTAG) with termination co- 
dons in all three reading frames. The blunted EcoRI- 
Hindlll fragment (Fig. 1) containing full-length E2 cDNA 
from the resulting plasmid was inserted into the blunt- 
ended unique BamHI site of pAcYM1 vector (29) to form 
the transfer vector pAcYM 1-E2. Recombinant baculovirus 
Ac-E2 was isolated and purified as described above. 
Sf9 cells infected with Ac-E2 were pulse-labeled with 
[sSS]methionine and chased with unlabeled methionine 
for 24 hr. The electrophoretic mobility of intracellular E2 
(36 kDa) increased slightly from 0 to 24 hr of chase (Fig. 
2B), suggesting that post-translational modification oc- 
curred. No full-length E2 was immunoprecipitated from 
the medium even after a 48-hr chase period (data not 
shown). The intracellular membrane-bound E2 after a 24- 
hr chase period was sensitive to endo H treatment (Fig. 
2B), but was partially resistant to endo H digestion after 
a 36-hr chase period (data not shown). 
To isolate sE2ATm for antigenicity and immunogenic- 
ity studies, Sf9 cells grown in Sf900 (Gibco-BRL) serum- 
free culture medium were infected with recombinant Ac- 
E2Z~Tm (m.o.i. = 5) and incubated at 27 ° for 78 hr. Ceils 
and culture supernatants were separated by low speed 
centrifugation and the pH of the supernatant was ad- 
justed to neutrality with 1 MTris-HCI (pH 8.0). An initial 
precipitation with (NH4)2SO4 to 20% of saturation was 
carried outto remove any lipid-like material in the culture 
medium (23). sE2ATm protein in the supernatant was 
fractioned by stepwise increases in the (NH4)2SO4 con- 
centration from 20 to 40% and 40 to 65% of saturation. 
The precipitates from each fraction were suspended in 
1/20 the original culture volume of TNE (10 mM Tris- 
HCI, pH 7.6, 0.15 M NaOl, 1 mM EDTA) and dialyzed 
against TNE at 4 ° overnight with two buffer changes. This 
resulted in the purification of sE2ATm protein to 80% 
homogenecity in the fraction between 20 and 40% satura- 
tion with (NH4)2SO4, as visualized by silver staining an 
SDS-PAGE gel (data not shown). The yield of purified 
sE2ATm was approximately 70% of the secreted protein 
in the culture medium. 
The antigenic properties of baculovirus-expressed RV 
E2z~Tm proteins were investigated. Both iE2ATm and 
sE2ATm forms were recognized by an E2-specific mono- 
clonal antibody and human anti-RV sera (data not 
shown). The purified sE2ATm protein was used as an 
antigen in immunoblot analysis to detect E2 antibodies 
in human sera from individuals of known immune status 
(30). The intensity of the reaction varied slightly between 
individuals with weak to no recognition in sera 4, 10, 
and 14 and strong recognition by an individual with CRS 
(serum 9) (Fig. 3A). ORS patients are known to have ex- 
ceptionally high levels of anti-E2 antibodies (6). The anti- 
genic properties of purified sE2ATm were compared 
with those of E2 from purified RV virions. Approximately 
equal amounts of RV proteins from RV virions versus 
sE2ATm protein were used in the immunoblotting. The 
correlation of the reactivities between E2 from RV virions 
and the recombinant sE2ATm was good (Fig. 3A), indi- 
cating that sE2ATm protein has similar antigenic activity 
to the wild-type E2 from RV virion. We have used sE2ATm 
as a target antigen in enzyme-linked immunosorbent 
assays (ELISA) for serological detection of E2-specific 
antibodies in the same sera. The ELISA mean ab- 
sorbance values obtained for sera 1 to 15 were 0.46, 
0.67, 0.32, 0.31, 0.63, 0.32, 0.52, 0.7, 0.8, 0.21, 0.56, 0.27, 
0.33, 0.44, and 2.27, respectively, with pooled human neg- 
ative sera having the value of 0.057. Although the com- 
parison could not be made quantitatively due to the na- 
ture of experimental conditions used, it demonstrated the 
potential of sE2ATm to be used as a target antigen in 
serological assays for RV infection. 
To study the immunogenicity of sE2ATm, BALB/c mice 
were subcutaneously inoculated with 5 #g of purified 
sE2ATm emulsified in 100 #1 of complete Freund's adju- 
vant (CFA), or phosphate-buffered saline in 100 #1 CFA 
in control animals. Mice received three additional injec- 
tions of antigen or saline in Freund's incomplete adjuvant 
at 3-week intervals. Mice were bled and sera collected 
for analysis. The presence of antFRV E2 antibodies was 
determined by immunoblot analysis. Mice immunized 
wi:th sE2Z~Tm produced antibodies against sE2ATm as 
well as E2 from RV virions (Fig. 3B), indicating that the 
antigenic structure of sE2ATm is similar to that of E2 
in the virion. In order to further confirm the antigenic 
properties of sE2ATm, we have analyzed the reactivity 
of anti-E2 sera raised by immunizing mice with RV E2 
isolated from RV virion by preparative SDS-PAGE (11). 
Anti-sera raised from denatured E2 from RV virions failed 
to recognize E2 from RV virion or sE2ATm (data not 
shown), confirming that the antigenicity of sE2ATm is 
preserved. The presence of virus neutralizing antibodies 
in mouse sera was determined by immunocytochemical 
focus assay. No viral neutralization activity was observed 
in the sera from mice immunized with sE2z~Tm (data not 
shown). This finding is consistent with our data obtained 
from mice immunized with a vaccinia recombinant virus 
expressing full-length RV E2 protein (unpublished data). 
The glycosylation of RV E2 in the virion is heteroge- 
neous (31). The two species of sE2Z~Tm observed may 
be due to the difference in oligosaccharide processing. 
Lectin-binding assays in conjunction with treatment with 
glycosidases were used to define the gtycans present 
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FiG. 3. Immunogenicity of sE2ATm. (A) Immunoblot analysis of purified sE2ATm with human sera. Purified RV particles or sE2ATm were separated 
on 11% SDS-PAGE under reducing conditions, transferred to nitrocellulose membranes, and tested for their immunoreactivities to human sera from 
individuals with wild-type RV infection (lanes 1-5), with congenital rubella syndrome (lanes 6-10), or healthy normal (lanes 11-15). M is the strip 
probed with E2 monoclonal antibodies. Strips probed with pooled human positive (+) and negative (-) sera, are indicated. Human sera were used 
at 1,60 dilution. (B) Immunoblot analysis of sE2ATm antisera. Strips containing separated RV proteins (lanes 1 and 3) or sE2ATm (lanes 2 and 4) 
were probed with human negative sera (A, lanes 1 and 2); human anti-RV sera (1,100 dilution) (A, lanes 3 and 4), mouse preimmune sera (B, lanes 
1 and 2) or sE2ATm mouse antisera (1,50 dilution) (19, lanes 3 and 4). Positions of proteins corresponding to viral El, E2, and C as well as secreted 
sE2ATm are indicated. Positions of molecular weight markers are shown (kDa). 
on the sE2ATm. The lectins used for glycan differentia- 
tion were the agglutinins of Galanthus nivalis (GNA), 
Sarnbucus nigra (SNA), Maaekia amurensis (MAA), Da- 
tura stramonium (DSA), and peanut (PNA) (32). GNA, 
which interacts with terminally linked mannose, bound 
both forms of sE2ATm even after digestion with O-gly- 
cosidase,-an enzyme which-releases the galactose/~(1- 
3) N-acetylgalactosamine (Gal/~(1-3)GalNAc) unit from 
0-glycans (Figs. 4A and 40). GNA did not bind sE2ATm 
after digestion with N-glycanase (Fig. 40), an enzyme 
that cleaves all N-linked glycans, suggesting that both 
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FIG. 4. Differentiation of glycan linkages on secreted E2~&Tm. Purified 
sE2ATm (33 and 30 kDa) was separated by SDS-PAGE, transferred 
to nitrocellulose, and probed with (A) lectins GNA, SNA, MAA, PNA, or 
DSA. sE2ATm was treated with buffer, lane C; H, endo H; N, N-glyca- 
nase; or O, O-glycosidase and then probed with human anti-RV sera 
(B), lectin GNA (C), or lectin PNA (D). Positions of molecular weight 
markers are shown (kDa). 
forms of sE2ATm contained terminal mannose residues 
in high-mannose and/or hybrid-type oligosaccharide 
chains. SNA and MAA, which bind to ~(2-6) and ez(2- 
3) sialic acid residues, did not bind sE2ATm (Fig. 4A). 
DSA, which binds to galactose /g(1-4) N-acetylglucos- 
amine (Gal~(1-4)GIcNAc) present in complex and hybrid 
N-glycan structures but not to high mannose type struc- 
tures, was found not to recognize recombinant sE2ATm 
(Fig. 4A), indicating that no complex N-linked structures 
were present on these glycoproteins. Complex oligosac- 
charide side chains found on glycoproteins from verte- 
brate hosts are usually replaced in insect cells by small 
truncated side chains and it has been shown that insect 
cells cannot sialylate oligosaccharide chains (28). PNA, 
which recognizes Gal/g(1-3)GalNAc, the core unit of O- 
glycans, bound only to the 33 kDa but not the 30 kDa 
form of sE2ATm (Fig. 4A). Digestion with O-glycosidase 
abolished the binding of PNA to the 33-kDa sE2ATm 
glycoprotein, whereas digestion with N-glycanase did 
not (Fig, 4D). These results suggest that the 33-kDa 
sE2ATm contained both N-linked and O-linked glycans, 
while the 30-kDa sE2ATm contained only N-linked 
glycan. 
Removal of both O-linked and N-linked glycans by 
treatment with N-glycanase followed by O-glycosidase 
did not completely reduce the molecular weight of 
sE2ATm from 33 to 25 kDa as expected for unglycosyl- 
ated sE2ATm (Fig. 5A, lane N + O). In contrast, a 29- 
kDa form of sE2ATm was observed which did not bind 
to either PNA (Fig. 5B) or GNA (Fig. 40, and data not 
shown). It is possible that this 29-kDa form of sE2ATm 
may contain more complex O-glycan structures where 
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FIG. 5. Glycan linkages on intracellular E2 proteins. Intraceltular 
membrane-bound E2 (E2) or secreted E2ATm (sE2ATm) was digested 
with glycosidases, eparated on 11% SDS-PAGE under educing con- 
ditions, and transferred to nitrocellulose membranes. The membranes 
were probed with human anti-RV serum (A), or with PNA (B). Samples 
treated with N-glycanase (lane N), O-glycanase (lane O), N-glycanase 
followed by O-glycosidase (lane N + O), or buffer only (lane C) are 
indicated. Mobilities of protein standards are shown (kDa). 
Gal/~(1-3)GalNAc is substituted by fucose, galactose, or 
N-acetyl-glucosamine (33), which must be removed by 
the respective exoglycosidases in order to make the core 
disaccharide accessible to PNA. However, treatment of 
29-kDa sE2ATm with ~-L-fucosidase or a-galactosidase 
prior to O-glyc.osidase digestion did not affect its electro- 
phoretic mobility (data not shown), suggesting that this 
29-kDa species may not contain more complex O-gty- 
cans and may contain another form of oligosaccharide 
chain which is not cleaved by N-glycanase (34). Further 
studies are required to address this question. 
O-linked oligosaccharides are added monosaccharide 
by monosaccharide to the polypeptide backbone, starting 
typically with N-acetylgalactosamine (GalNAc) and ga- 
lactose. The available data suggest that the addition of 
the core GalNAc can take place both in the ER and in 
the Golgi apparatus (35, 36). The acquisition of O-linked 
glycosylation on both intracellular membrane-bound E2 
and iE2ATm was studied by treatment of both proteins 
(harvested after 70 hr postinfection) with N-glycanase 
and O-glycosidase, followed by binding to PNA after the 
digested protein samples were transferred to the mem- 
branes, No O-linked sugars were detected in either mem- 
brane-bound E2 (Fig. 5) or iE2ATm (data not shown). It 
appears that O-linked glycosylation of RV E2 protein in 
insect cells may occur in late stages of glycoprotein pro- 
cessing beyond the medial Golgi compartments as both 
intracellular membrane-bound E2 and iE2ATm were par- 
tially endo H-sensitive (24). It is interesting that a protein 
species partially resistant to N-glycanase was also ob- 
served in membrane-bound E2 (Fig. 5). 
in this study, we have expressed RV E2 envelope pro- 
tein as a soluble and membrane-bound protein in recom- 
binant baculovirus-infected insect cells. Our results dem- 
onstrate that the antigenicities of purified sE2/kTm corre- 
late well with the wild-type E2 antigen from RV virion. 
The requirement for fetal bovine serum in conventional 
cell culture media hinders the direct use and purification 
of recombinant proteins, as fetal bovine serum contains 
a spectrum of proteins. The production and secretion of 
sE2/kTm into the serum-free medium using an insect cell 
system resulted in an antigen with very low concentration 
of extraneous proteins that facilitated isolation of large 
quantities of antigenic E2 (5 mg/liter), not easily obtained 
by using the COS cell expression system (13) or isolating 
E2 protein from purified RV virions. The secreted form of 
E2 is valuable for biochemical studies of E2 and as a 
target antigen for the laboratory diagnosis of acute and 
congenital rubella infections. 
it has been shown that under certain conditions, insect 
cells are capable of producing recombinant proteins that 
contain N-linked complex-type oligosaccharides equiva- 
lent to those found in mammalian ceils (37), However, 
no complex N-linked structures were found on sE2ATm 
(Fig. 4). We have shown previously that N-linked glycosyl- 
ation is essential for proper intramolecular disulfide 
bonding to promote correct folding of RV E2 as well as 
for the secretion of E2 from COS cells (9). It appears 
that the small N-linked oligosaccharide side chains in 
sE2ATm can function as well in maintaining proper con- 
formation of E2 for its antigenicity and secretion. The role 
of heterogeneous glycosylation and O-linked glycosyla- 
tion in the antigenicity and processing of RV E2 protein 
remains to be determined. Further characterization of the 
two soluble forms of E2ATm may provide information on 
the importance of the glycosylation pattern of E2 to the 
biological properties of RV. 
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